Übersetzung von "platelet derived" zur englischen Sprache:

Wörterbuch Deutsch-Englisch

Platelet derived - Übersetzung :

Beispiele (Externe Quellen, nicht überprüft)

Imatinib hemmt auch die Tyrosinkinase Aktivität des PDGF Rezeptors (platelet derived growth factor, PDGF) und des Rezeptors für Stammzellfaktor (stem cell factor, SCF), c Kit, und inhibiert PDGF und SCF vermittelte zelluläre Reaktionen.	Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet derived growth factor (PDGF), PDGF R, and stem cell factor (SCF), c Kit, and inhibits PDGF and SCF mediated cellular events.
Plasma derived medicinal products	vaccines Plasma derived medicinal products
Preclinical safety evaluation of biotechnology derived pharmaceuticals	Preclinical safety evaluation of biotechnology derived
Treatment of peritumoral edema derived form brain tumour	Treatment of peritumoral edema derived form brain tumour
Safety and Supply of Plasma derived Medicinal Products	Safety and Supply of Plasma derived Medicinal Products
New variant CJD and plasma derived medicinal products	Report on selection of influenza vaccines strains for 1998 99
Note for guidance on plasma derived medicinal products	Note for guidance on plasma derived medicinal products
Titel Note for guidance on plasma derived medicinal products	Note for guidance on plasma derived medicinal products
Plasma derived medicinal products Verabschiedet im März 1996 (Überarbeitung)	Adopted in February 96
Sunitinib ist ein Hemmer des PDGF(platelet derived growth factor) Rezeptors α und β, des VEGF(vascular endothelial growth factor) Rezeptors 1 3, des KIT(Stammzellfaktor) Rezeptors, des FLT(Fms like tyrosine kinase)3 Rezeptors, des CSF (koloniestimulierenden Faktors)1 Rezeptors und des RET(rearranged during transfection) Rezeptors.	Sunitinib was identified as inhibitor of platelet derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms like tyrosine kinase 3 (FLT3), colony stimulating factor receptor (CSF 1R), and the glial cell line derived neurotrophic factor receptor (RET).
Sunitinib ist ein Hemmer des PDGF(platelet derived growth factor) Rezeptors α und β, des VEGF(vascular endothelial growth factor) Rezeptors 1 3, des KIT(Stammzellfaktor) Rezeptors, des FLT(Fms like tyrosine kinase)3 Rezeptors, des CSF(koloniestimulierenden Faktors)1 Rezeptors und des RET(rearranged during transfection) Rezeptors.	Sunitinib was identified as an inhibitor of platelet derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms like tyrosine kinase 3 (FLT3), colony stimulating factor receptor (CSF 1R), and the glial cell line derived neurotrophic factor receptor (RET).
Sunitinib ist ein Hemmer des PDGF(platelet derived growth factor) Rezeptors α und β, des VEGF(vascular endothelial growth factor) Rezeptors 1 3, des KIT(Stammzellfaktor) Rezeptors, des FLT(Fms like tyrosine kinase)3 Rezeptors, des CSF(koloniestimulierenden Faktors)1 Rezeptors und des RET(rearranged during transfection) Rezeptors.	Sunitinib was identified as inhibitor of platelet derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms like tyrosine kinase 3 (FLT3), colony stimulating factor receptor (CSF 1R), and the glial cell line derived neurotrophic factor receptor (RET).
for Guidance on the Clinical investigation of human plasma derived	Treament of acute myeloid leukaemia
Note for guidance on the clinical investigation of plasma derived fibrin sealants	EMEA CPMP BPWG 1089 00 Note for guidance on the clinical investigation of plasma derived fibrin sealants
Core SPC for Human plasma derived antithrombin Zur Stellungnahme freigegeben im Dezember 2000	Treatment of N acetylglutamate synthetase (NAGS) deficiency
Note for guidance on comparability of medicinal products containing biotechnology derived proteins as drug substance	Note for guidance on comparability of medicinal products containing biotechnology derived proteins as drug substance
Titel des Dokuments Note for Guidance on the Clinical Investigation of Plasma derived Antithrombin Products	Note for Guidance on the Clinical Investigation of Plasma derived Antithrombin Products
Note for Guidance on Comparability of Medicinal Products Containing Biotechnology derived Proteins as Drug Substance	Note for Guidance on Comparability of Medicinal Products Containing Biotechnology derived Proteins as Drug Substance
Core SPC for Human plasma derived and recombinant coagulation factor VIII products Verabschiedet im Juni 2000	26.05.2000 31.07.2000 13.09.2000 45 days
Core SPC for Human plasma derived and recombinant coagulation factor IX products Verabschiedet im Juni 2000	Gemtuzumab ozogamicin
evaluation of biotechnological products derived from cell lines of human or animal origin Quality of biotechnological biological products	evaluation of biotechnological products derived from cell lines of human or animal origin Quality of biotechnological biological products
Titel des Dokuments Note for Guidance on the Clinical investigation of plasma derived fibrin sealants Note for guidance on the Clinical investigation of von Willebrand factor Warning on transmissible agents for patient leaflets and SPCs Core SPC for Plasma derived fibrin sealants	(CPMP EWP 559 95) methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia
Preclinical safety evaluation of biotechnology derived pharmaceuticals Non clinical safety studies for the conduct of human clinical trials for pharmaceuticals	Non clinical safety studies for the conduct of human clinical
Concept paper on gene therapy Concept paper on the development of a CPMP guideline on comparability of b iotechnology derived products	Guidelines Concept paper on gene therapy Concept paper on the development of a CPMP guideline on comparability of biotechnology derived products
detection of hepatitis C virus RNA in p lasma pools (addendum to note for guidance on plasma derived medic inal products)	detection of hepatitis C virus RNA in plasma pools (addendum to note for guidance on plasma derived medicinal products)
Report of the EMEA Expert Workshop on human TSEs and plasma derived medicinal products, 15 16 Mai 2000 Verabschiedet im Juli 2000	Commission Opinion received Date of Designation
a statement A follows semantically from a set of premises Γ (formula_153) iff the sequent formula_154 can be derived by the above rules.	a statement formula_88 follows semantically from a set of premises formula_89 formula_90 iff the sequent formula_91 can be derived by the above rules.
Core SPC for Human Plasma derived Antithrombin Note for Guidance on the Clinical Investigation of Human Normal Immunoglobulin for Subcutaneous and Intramuscular use	Note for Guidance on the Clinical Investigation of Human Normal Immunoglobulin for Subcutaneous and Intramuscular use
Die ESPRIT (Enhanced Suppression of the Platelet IIb IIIa Receptor with Eptifibatid Therapy) Studie war eine randomisierte, placebokontrollierte Doppelblindstudie (n 2.064) für die Indikation nicht notfallmäßige PCI mit intrakoronarem Stenting.	ESPRIT (Enhanced Suppression of the Platelet IIb IIIa Receptor with eptifibatide Therapy) was a double blind, randomised, placebo controlled trial (n 2,064) for nonurgent PCI with intracoronary stenting.
Efficacy and safety of human plasma derived factor VIII.c Verabschiedet im Februar and IX.c products in clinical trials in haemophiliacs before 1996 and after authorisation	Efficacy and safety of human plasma derived factor VIII. c and IX. c products in clinical trials in haemophiliacs before and after authorisation
Contribution to part S.2.3 of the structure of the dossier for applications for marketing authorisation control of starting materials for the production of plasma derived medicinal products	Contribution to part S.2.3 of the structure of the dossier for applications for marketing authorisation control of starting materials for the production of plasma derived medicinal products
Titel des Dokuments Position Paper on the Non clinical safety studies to support clinical trials with a single low dose of a compound Note for Guidance on specification limits for residues of metal catalysts Note for Guidance on Comparability of Medicinal Products Containing Biotechnology derived Proteins as Drug Substance	Points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population Note for guidance on the evaluation of the pharmacokinetics of

Display this page in English